AD_____

Award Number: DAMD17-01-1-0538

TITLE: Oncogenic Members of pp32 Family, the Widely Applicable Targets for Immunotherapy in Human Breast Cancer

PRINCIPAL INVESTIGATOR: Jining Bai, Ph.D.

CONTRACTING ORGANIZATION: The Johns Hopkins University
School of Medicine
Baltimore, Maryland 21205

REPORT DATE: June 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED
	June 2002	Final (15 May 01 - 14 May 02)

4. TITLE AND SUBTITLE
Oncogenic Members of pp32 Family, the Widely Applicable Targets for Immunotherapy in Human Breast Cancer

5. FUNDING NUMBERS
DAMD17-01-1-0538

6. AUTHOR(S)
Jining Bai, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
The Johns Hopkins University
School of Medicine
Baltimore, Maryland 21205
E-Mail: jnbai@jhmi.edu

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. Abstract ***(Maximum 200 Words)*** *(abstract should contain no proprietary or confidential information)*

This study is the initial phase of a feasibility study of a novel immunotherapeutic strategy for the treatment of breast cancer. The rationale is based upon recent findings that genes belonging to the pp32 family are differentially and alternatively expressed in most human breast cancers. In general, benign breast tissues express pp32, a tumor suppressor, whereas breast cancers express tumorigenic family members, including pp32r1 and pp32r2. Since pp32r1 and pp32r2 are expressed in nearly all breast cancers, but not in normal adult tissues, they may reasonably serve as targets for antigen-specific immunotherapy. The purpose of this study is to identify tumor-associated antigens (TAA) in pp32r1 and pp32r2, then test their suitability *in vitro* as immunotherapeutic targets in breast cancer. Currently, the second phase of (*in vivo*) feasibility is underway. If successful, the results may translate into eventual clinical trials of peptide vaccines or adoptive T cell therapy

14. SUBJECT TERMS
TAA, Immunotherapy

15. NUMBER OF PAGES
12

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

Table of Contents

Introduction:

In this concept proposal, we proposed a feasibility study of a novel immunotherapeutic strategy for the treatment of breast cancer. The rationale is based upon recent findings that genes belonging to the pp32 family are differentially and alternatively expressed in most human breast cancers. In general, benign breast tissues express pp32, a tumor suppressor, whereas breast cancers express tumorigenic family members, including pp32r1 and pp32r2. Since pp32r1 and pp32r2 are expressed in nearly all breast cancers, but not in normal adult tissues, they may reasonably serve as targets for antigen-specific immunotherapy.

Body:

Since Statement of Work is not available for Concept Proposal, the list of Specific Aims will be used to report the progress of this project.

1) Specific Aim #1: Identify, synthesize and test candidate peptides that could potentially bind to HLA class I molecules based on the coding sequence of pp32r1 and pp32r2.
Using Bioinformatics and ImMunoGeneTics tools, we analyzed the entire coding region of pp32, pp32r1 and pp32r2 genes for binding affinity with HLA-A*0201 molecule as well as the degradation pattern by proteasomal cleavages. The result of calculation shown (Table 1) that 19 motifs are potentially favorable of binding to HLA-A*0201 molecule with high affinity. To verify the prediction *in vitro*, HLA-A*0201+ TAP-deficient T2 hybridoma (ATCC) was pulsed with 50ug/ml of each peptide representing the motif (or control) and 5ug/ml of b2-microglobulin for 18hr at 37 C. HLA-A*0201 expression was then measured by flow cytometry using mAb BB7.2 (ATCC) followed by incubation with FITC-conjugated secondary antibody. Fluorescent index of HLA-A*0201 to each peptide can be determined as: (mean fluorescence with peptide - mean fluorescence without peptide) / (mean fluorescence without peptide). The result shown 10 out of 19 motifs is capable of binding to HLA-A*0201 in a concentration dependent manner (Table 1).

2) Screen for candidate pp32r1 & pp32r2 peptides that fulfill the requirements for TAA.
In order to be qualified as a TAA, a motif has to be able to meet several criteria in addition to the binding to HLA-A*0201. These requirements include (i) the antigen can be naturally processed by tumor cells, (ii) it permits expansion of antigen-specific CTL; (iii) it is presented in a MHC-restricted fashion. CTL assay was carried out to test if the motifs identified in Aim#1 fulfill the requirements for TAA. In brief, Cr^{51}-labeled target cells (T2 cells pulsed with peptide or cancer cell expressing pp32 family members) were incubated with various numbers of CTL effecter cells for 4 hr. Cr^{51}-release assays were performed in triplicate per condition using $5x10^3$ labeled target cells per well in a 96-well plate. Percent specific lysis will be calculated from CPM of (experimental result - spontaneous release)/(maximum release - spontaneous release). The results, summarized in Table 2, indicate that 2 out of 10 motifs fulfilled the above requirement as TAA.

3) Evaluate whether the pp32r1- or pp32r2- specific CTL can recognize a broad range of breast tumors (optional).
As an optional study proposed in the Concept Project, this study is currently under way in the PI's Lab to evaluate the widely applicability of the identified candidate TAA.

Key Research Accomplishments:

We have identified two peptide motifs from pp32 family members, which fulfill the requirement to be TAAs. This study (mostly *in vitro*) provided bases for further *in vivo* validation in breast cancer animal models.

Reportable Outcomes:

After the completion of the 3rd Specific Aim (Optional), we are expected to apply for U.S. Patent provision and to publish the results supported by this Concept Award.

Conclusions:

We demonstrated in vitro that (i) the oncogenic pp32 family members can be presented by HLA-A*0201, (ii) the HLA-A*0201 cells bearing these motifs can be recognized and lyzed by pp32r1- or pp32r2- specific CTL in a MHC class I specific manner.

Peptide	BIMAS Score	LpRep Score	FPEITHI Score	Binding to T2 Cells
0801-01	3499.535	3.37	26	+
0801-02	1591.602	2.46	22	-
0801-03	805.719	5.76	17	+
0801-04	681.542	3.54	28	+
0801-05	636.316	4.19	25	+
0801-06	445.216	6.90	27	-
0801-07	481.542	3.13	26	+
0801-08	432.319	4.87	21	-
0801-09	399.682	7.69	23	+
0801-10	379.216	5.81	13	-
0801-11	301.331	3.12	27	+
0801-12	281.542	3.47	22	-
0801-13	264.498	6.72	24	+
0801-14	226.014	3.54	20	-
0801-15	212.775	6.43	19	+
0801-16	172.752	6.81	21	+
0801-17	148.896	5.87	24	-
0801-18	139.730	6.72	19	-
0801-19	105.719	7.99	18	-
MGA1 (P.Ctrl)	734.189	4.86	26	+
ID9 (N.Ctrl)	0.000	n/a	1	-

Table 1. Predicted HLA-A*0201 Binding Motifs and Their Ability to Bind T2 Cells.

Peptide	CTL Lysis	Processing	CTL Expansion	MHC I Restriction
0801-01	+	n/a	Yes	n/a
0801-03	+++	Yes	Yes	Yes
0801-04	+	n/a	Yes	n/a
0801-05	+	n/a	Yes	n/a
0801-07	+++	Yes	Yes	Yes
0801-09	+	n/a	Yes	n/a
0801-11	-	n/a	No	n/a
0801-13	+	n/a	Yes	n/a
0801-15	-	n/a	No	n/a
0801-16	-	n/a	No	n/a
MGA1 (P.Ctrl)	+++	Yes	Yes	Yes
ID9 (N.Ctrl)	-	No	No	No

Table 2. Summary of CTL Assays for Motifs That are Capable of Binding to HLA-A*0201

Summary of Personnel Partially Supported by This Concept Award:

1) Jining Bai (PI)
2) Adetinuke Jagun (Technician)

CURRICULUM VITAE

Name: Jining Bai

Current Appointment:
Assistant Professor
Department of Pathology
Johns Hopkins University School of Medicine

Addresses:

Office:
Division of Molecular Pathology
Department of Pathology
Johns Hopkins School of Medicine
Room B-302
418 N. Bond Street
Baltimore, MD 21205
Phone: (410) 955-6920
Fax: (410) 502-5158
E-mail: jnbai@jhmi.edu

Home:
8641 Willow Oak Road
Baltimore, MD 21234
Phone: (410) 882-4638

Education & Training:

1983-1988	B. Eng., Department of Engineering Physics, Tsinghua University, Beijing, P. R. China
1990-1996	Ph.D. / Graduate studies, Department of Biophysics, Johns Hopkins University Baltimore, MD
1996-1999	Post-doctoral Fellow, Division of Molecular Pathology Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD

Professional Experiences:

1985-1986	Instructor, Computer programming School of Professional Studies Tsinghua University, Beijing, P. R. China
1986-1988	Research assistant, Institute of Material Sci. & Tech., Tsinghua University, Beijing, P. R. China
1988-1990	Graduate studies, Department of Biol. Sci. & Tech., Tsinghua University, Beijing, P. R. China
1989-1990	Teaching assistant, Biology Lab, Department of Biol. Sci. Tsinghua University, Beijing, P. R. China
1991-1995	Pre-doctoral Fellow, Department of Embryology Carnegie Institution of Washington, Baltimore, MD
1992-1993	Teaching Assistant, Reproductive Physiology Johns Hopkins University.
1996-2000	Research Fellow, Division of Molecular Pathology Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD
2000-2001	Research Associate, Division of Molecular Pathology Department of Pathology, Johns Hopkins Medical Institutions Baltimore, MD
2001- 2002	Instructor, Division of Molecular Pathology Department of Pathology, Johns Hopkins Medical Institutions Baltimore, MD
2002-	Assistant Professor, Division of Molecular Pathology Department of Pathology, Johns Hopkins Medical Institutions Baltimore, MD

Bibliography:

Refereed Publications

Bai J, Brody JR, Kadkol SS, Pasternack GR. Tumor suppression and potentiation by manipulation of pp32 expression. *Oncogene*, 20 (17):2153-60, 2001.

Bai, J., Kadkol, S. S., Brody, J. R. & Pasternack, G. R., pp32 gene family. *Encycl. Mol. Medicine,* Vol.4, 2564-2565, 2001.

Kadkol SS, El Naga GA, Brody JR, Bai J, Gusev Y, Dooley WC, Pasternack GR. Expression of pp32 gene family members in breast cancer. *Breast Cancer Res Treat.* 68(1):65-73, 2001.

Kadkol SS, Brody JR, Pevsner J, Bai J, and Pasternack GR Modulation of oncogenic potential by alternative gene use in human prostate cancer. *Nature Medicine* 5(3):275-279, 1999.

Bai J., Pagano RE. Measuring the spontaneous transfer and transbilayer movement of BODIPY-labeled lipids in liposome vesicles, Biochemistry. (36):8840-8848, 1997

Ding, J. R., Zhou, X., Bai, J., Liu, B. X. Amorphous niobium monoxide films prepared by reactive evaporation, *J. Vac. Sci. Tech.* 8:3349-51, 1990.

Absracts

Bai, J., Kadkol, S. S., Brody, J. R. & Pasternack, G. R. pp32 Gene family at the crossroad of oncogenesis and tumor suppression. *Proc. of NCC,* 2:151, 2000.

Bai, J., Kadkol, S. S., Brody, J. R. & Pasternack, G. R. alterations in pp32 gene family – A novel molecular targets in breast cancer therapy. *Proc. of 4th NMC*, SGK Foundation, 4:22, 2000.

Kadkol, S. S., Saria, E. A., Brody, J. R., Bai, J. & Pasternack, G. R.. Analysis of alternative pp32 gene use in breast cancer. *J. of Mol. Diagnostics* 1:58, 1999

Bai, J., Kadkol, S. S., Brody, J. R. & Pasternack, G. R. Modulation of Oncogenic Potential *in vitro* and *in vivo* by pp32. *Proc. AACR.* 90:574, 1999

Kadkol, S. S., Brody, J. R., Bai, J. & Pasternack, G. R. Heterogeneous expression of members of the closely-related pp32 gene family in prostate cancer and adjacent normal prostate. *Am. J. Pathol.* 153:1660, 1998

Bai, J. , Kadkol, S. S., Brody, J. R., Chamberlin, M., Cheong, R. & Pasternack, G.R. Cell- Type Specific Suppression of Proliferation of Human Prostatic Adenocarcinoma Cell by a Novel Tumor Suppressor pp32. *Proc. AACR.* Supl. 10:A-10, 1998

Invention & Patents:

Pasternack, G.R. & Bai, J. Method of Treating Cancer by Restoration of pp32 Function, *United States Patent & Trademark Office (USPTO)*, #60/118667, 1999.

Grants & Contracts:

Current:

1) National Research Award — Komen Foundation — Principal Investigator
Active — (12/99-06/02) — $100,000 (annual direct)
Development of Novel Therapeutic Target and Approach for Breast Cancer
– Repairing Common Defects in Breast Cancer by Restoration of pp32.

2) IRG — JHMI — Principal Investigator
Active — (05/01-05/03) — $20,000 (annual direct)
Development of a Novel Transgenic Mouse Model for Human Prostate Cancer

3) Idea Award — DOD/CDMRP — Principal Investigator
Active — (10/01-10/04) — $100,000 (annual direct)
Identification of Widely applicable Tumor- Associated Antigens for Breast Cancer ImmunoTherapy.

4) Pilot Award — Breast Cancer SPORE/oncology — Principal Investigator
Active — (04/02-04/03) — $40,000 (annual direct)
HOXB7, Widely Applicable Targets for Immunotherapy against Breast Cancer.

Pending:

1) RO1 — NIH — Principal Investigator
Pending — (01/03-12/06) — $225,000 (annual direct)
Localization and Molecular Interaction of pp32 Family Members

Complete:

1) Concept Award — DOD/CDMRP — Principal Investigator
Active — (05/01-06/02) — $50,000 (annual direct)
Oncogenic Members of pp32 gene family, Widely Applicable Targets for Immunotherapy against Breast Cancer.

Honors & Awards:

Honored Student, Tsinghua University (1983-1988)
Outstanding College Graduate Award, National Education Commission of China (1988)
Winner of Natural Philosophy Competition, Tsinghua University (1990)
Travel Award, European Symposium in Signal Transduction (1991)
Carnegie Fellowship, Carnegie Institution of Washington (1990-1991)
Dean's Fellowship, Johns Hopkins University (1990-1995)
Pathology Fellowship, Johns Hopkins Medical Institution (1996-1999)
National Research Award, Susan G. Komen Breast Cancer Foundation (1999-2001)
Concept Award, Congressionally Directed Medical Research (2000-2001)
Idea Award, Congressionally Directed Medical Research (2001-2004)

Invited Lectures:

1) Alterations in pp32 Gene Family – A Novel Molecular Targets in Breast Cancer Therapy.
The 4th National Mission Conference for Breast Cancer
Washington D.C.
September, 2000

2) pp32 Gene Family, Potential Therapeutic Targets for Breast Cancer and Prostate Cancer .
National Cancer Institute
Beijing, P.R. China
October, 2000

3) pp32 Gene Family at the Crossroad of Oncogenesis and Tumor Suppression.
The Cancer Congress 2000
Beijing, P.R.China, October, 2000